Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1

Interleukin (IL)-13 is a key mediator of tissue fibrosis caused by T helper cell type 2 inflammation. We hypothesized that the fibrogenic effects of IL-13 are mediated by transforming growth factor (TGF)-β. To test this hypothesis we compared the regulation of TGF-β in lungs from wild-type mice and CC10-IL-13 mice in which IL-13 overexpression causes pulmonary fibrosis. IL-13 selectively stimulated TGF-β1 production in transgenic animals and macrophages were the major site of TGF-β1 production and deposition in these tissues. IL-13 also activated TGF-β1 in vivo. This activation was associated with decreased levels of mRNA encoding latent TGF-β–binding protein-1 and increased mRNA encoding urinary plasminogen activator, matrix metalloproteinase (MMP)-9, and CD44. TGF-β1 activation was abrogated by the plasmin/serine protease antagonist aprotinin. It was also decreased in progeny of crosses of CC10-IL-13 mice and MMP-9 null mice but was not altered in crosses with CD44 null animals. IL-13–induced fibrosis was also significantly ameliorated by treatment with the TGF-β antagonist soluble TGFβR-Fc (sTGFβR-Fc). These studies demonstrate that IL-13 is a potent stimulator and activator of TGF-β1 in vivo. They also demonstrate that this activation is mediated by a plasmin/serine protease- and MMP-9–dependent and CD44-independent mechanism(s) and that the fibrogenic effects of IL-13 are mediated, in great extent, by this TGF-β pathway.

[1]  I. Grzelewska-Rzymowska,et al.  [Airway remodeling in asthma]. , 2003, Pneumonologia i alergologia polska.

[2]  K. O'Reilly,et al.  Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. , 2001, Clinical immunology.

[3]  K. Ohshima,et al.  Interleukin‐13 and interleukin‐13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis , 2001, Histopathology.

[4]  N. Khalil,et al.  Post translational activation of latent transforming growth factor beta (L-TGF-beta): clinical implications. , 2001, Histology and histopathology.

[5]  I. N. Brown,et al.  Contribution of Th1 and Th2 Cells to Protection and Pathology in Experimental Models of Granulomatous Lung Disease1 , 2001, The Journal of Immunology.

[6]  S. Maxwell,et al.  Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. , 2001, Journal of cell science.

[7]  B. Ma,et al.  Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. , 2000, The Journal of clinical investigation.

[8]  A. Kulkarni,et al.  Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing , 2000, Nature Medicine.

[9]  R. Homer,et al.  IL-11 Selectively Inhibits Aeroallergen-Induced Pulmonary Eosinophilia and Th2 Cytokine Production1 , 2000, The Journal of Immunology.

[10]  R. Silverstein,et al.  A CD36 synthetic peptide inhibits bleomycin-induced pulmonary inflammation and connective tissue synthesis in the rat. , 2000, American journal of respiratory cell and molecular biology.

[11]  J. Santibañez,et al.  Involvement of the Ras/MAPK signaling pathway in the modulation of urokinase production and cellular invasiveness by transforming growth factor-beta(1) in transformed keratinocytes. , 2000, Biochemical and biophysical research communications.

[12]  T. Wynn,et al.  IL-10 and the Dangers of Immune Polarization: Excessive Type 1 and Type 2 Cytokine Responses Induce Distinct Forms of Lethal Immunopathology in Murine Schistosomiasis , 2000, The Journal of Immunology.

[13]  L. Lichtenstein,et al.  Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. , 2000, The Journal of pharmacology and experimental therapeutics.

[14]  G. McKenzie,et al.  Schistosome Infection of Transgenic Mice Defines Distinct and Contrasting Pathogenic Roles for IL-4 and IL-13: IL-13 Is a Profibrotic Agent1 , 2000, The Journal of Immunology.

[15]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[16]  N. Khalil TGF-β: from latent to active , 1999 .

[17]  G. Gabbiani,et al.  Interferon-γ inhibits experimental renal fibrosis , 1999 .

[18]  S. Romagnani Th1/Th2 cells. , 1999, Inflammatory bowel diseases.

[19]  V. Koteliansky,et al.  In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  V. Petkov,et al.  A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. , 1999, The New England journal of medicine.

[21]  A. Ray,et al.  Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. , 1999, The Journal of clinical investigation.

[22]  H. Shirwan Chronic allograft rejection. Do the Th2 cells preferentially induced by indirect alloantigen recognition play a dominant role? , 1999, Transplantation.

[23]  T. Wynn,et al.  An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. , 1999, The Journal of clinical investigation.

[24]  S. Mai,et al.  Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. , 1999, The American journal of pathology.

[25]  R. D. du Bois,et al.  Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. , 1999, The European respiratory journal.

[26]  V. Koteliansky,et al.  Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. , 1999, Circulation research.

[27]  J. Sipley,et al.  Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.

[28]  M. Ferguson,et al.  Role of Elevated Plasma Transforming Growth Factor-β1 Levels in Wound Healing , 1999 .

[29]  R. Homer,et al.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. , 1999, The Journal of clinical investigation.

[30]  D. Rifkin,et al.  Proteolytic control of growth factor availability , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[31]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[32]  T. Wynn,et al.  IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. , 1999, Journal of immunology.

[33]  J. Munger The integrin αvβ6 binds and activates latent TGFβ1 : A mechanism for regulating pulmonary inflammation and fibrosis , 1999 .

[34]  E. Rieber,et al.  Th2 cells as effectors in postirradiation pulmonary damage preceding fibrosis in the rat. , 1999, International journal of radiation biology.

[35]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[36]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[37]  W. Wisden,et al.  Interleukin (IL)-4–independent Induction of Immunoglobulin (Ig)E, and Perturbation of  T Cell Development in Transgenic Mice Expressing IL-13 , 1998, The Journal of experimental medicine.

[38]  G. Canonica,et al.  Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. , 1998, The Journal of clinical investigation.

[39]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[40]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[41]  D. Clark,et al.  Transforming growth factor-beta (TGF-beta). , 1998, The international journal of biochemistry & cell biology.

[42]  G. Canonica,et al.  INTERLEUKIN (IL)-4 AND IL-13 ACT ON HUMAN LUNG FIBRO-BLAST , 1998 .

[43]  J. D. de Vries The role of IL-13 and its receptor in allergy and inflammatory responses. , 1998, The Journal of allergy and clinical immunology.

[44]  L. Armstrong,et al.  Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. , 1998, American journal of respiratory cell and molecular biology.

[45]  D. Rockey,et al.  Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. Mak,et al.  CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. , 1997, Blood.

[47]  A. Minty,et al.  The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. , 1997, European cytokine network.

[48]  A. Roberts,et al.  TGF-β: A Critical Modulator of Immune Cell Function☆ , 1997 .

[49]  R. Martin,et al.  Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. , 1997, American journal of respiratory cell and molecular biology.

[50]  P. Carmeliet,et al.  Involvement of u‐PA in the anti‐apoptotic activity of TGFβ for vascular smooth muscle cells , 1997, FEBS letters.

[51]  D. Rifkin,et al.  Latent transforming growth factor-beta: structural features and mechanisms of activation. , 1997, Kidney international.

[52]  S. Phan,et al.  Lung interleukin-5 expression in murine bleomycin-induced pulmonary fibrosis. , 1997, American journal of respiratory cell and molecular biology.

[53]  M. Fujimoto,et al.  Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. , 1997, The Journal of rheumatology.

[54]  R. Flavell,et al.  Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction. , 1996, The Journal of clinical investigation.

[55]  T. Kotsimbos,et al.  Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. , 1996, Proceedings of the Association of American Physicians.

[56]  N. Khalil,et al.  Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. , 1996, American journal of respiratory cell and molecular biology.

[57]  Kohei Moyazono Transforming Growth Factor-β, TGF-β , 1996 .

[58]  K. Flanders,et al.  TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. , 1996, American journal of respiratory cell and molecular biology.

[59]  T. Paavonen,et al.  Chronic Allograft Rejection , 1993 .

[60]  D. Lamb,et al.  A type 2 (Th2‐like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA) , 1995, Clinical and experimental immunology.

[61]  G. Trinchieri,et al.  Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. , 1995, Journal of immunology.

[62]  R. Coffman,et al.  IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. , 1995, Journal of immunology.

[63]  G. Gurujeyalakshmi,et al.  Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. , 1995, Experimental lung research.

[64]  S. Kasai,et al.  [Transforming growth factor (TGF)]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[65]  J. D. de Vries,et al.  Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. , 1994, Immunology today.

[66]  K. Flanders,et al.  Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. , 1991, American journal of respiratory cell and molecular biology.

[67]  M. Sporn,et al.  Transforming Growth Factor , 1990 .

[68]  N. Khalii Post translational activation of latent transforming growth factor beta ( L-TGF-B ) : clinical implications , 2022 .